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Introduction: Creutzfeldt-Jakob disease (CJD) is an ultimately fatal, neurodegenerative disease caused by misfolded
prion protein aggregation and accumulation. The development of amyotrophic features has been described in CJD,
though rarely as an early or prominent feature. Consequently, the significance of amyotrophy in prion disease
etiology remains unclear.
Case presentation: Our patient, a healthy 70-year-old French/Algerian man, presented to our hospital following a
work-related fall and was admitted with lower limb skeletal muscle atrophy and fasciculations; the fasciculations
progressed to involve the trunk, upper limbs and face. Within days, he developed evidence of a progressive
ascending neurological syndrome and subsequent brain involvement with supranuclear palsy of upgaze, catalepsy
and death 36 days after symptom onset. Amyotrophy remained the principle feature of his disease. Dementia
started to develop within 10 days of the onset of his amyotrophy. Prion disease was confirmed at postmortem.
Conclusions: Our observations suggest an unusual form of prion disease with prominent early involvement of
anterior horn cells, ascending prion propagation in the central nervous system and a grave prognosis.
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Creutzfeldt-Jakob disease (CJD) is a fatal neurodegenera-
tive disease characterized by rapidly progressive dementia
caused by prion protein propagation [1,2]. Amyotrophy is
characteristic of amyotrophic lateral sclerosis (ALS), al-
though its presence throughout the clinical course of CJD
has been described [3]. However, the significance of lower
motor neuron involvement in prion disease etiology is dis-
puted [4,5], and the suggestion of an amyotrophic variant
of the disease has been discredited [3,4]. Amyotrophy in
CJD has been viewed as a terminal phenomenon in
emancipated patients [4]; though Worrall et al. [3] high-
light the occasional predominance of amyotrophic fea-
tures throughout the disease course. Patients with the
suspicion of a prion disease and amyotrophy are im-
portant to study as they potentially expand the clinical
spectrum of the prionopathies.* Correspondence: research@ndr.org.au
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distribution, and reproduction in any mediumThis article charts the clinical course of marked early
amyotrophic features from symptomatic onset until our pa-
tient’s death. Fasciculations and muscle atrophy remained
prominent, with clinical evidence to suggest step-wise, as-
cending prion propagation from our patient’s lower limbs,
trunk, upper limbs and finally brain. A diagnosis of spor-
adic CJD was confirmed at postmortem.
Case presentation
A 70-year-old French/Algerian man presented to our hos-
pital following a work-related fall. He had full functional
capacity in all acts of daily living including driving, lived
independently and was working until the day of his pres-
entation. An initial physical examination revealed the pres-
ence of fasciculations in all muscles of the lower limbs,
warranting further investigation and admission. The pa-
tient had stable non-insulin-dependent diabetes mellitus.
An initial neurological assessment revealed normal cogni-
tion, speech and swallowing. An examination of his central
and peripheral nervous systems revealed no diagnostic ab-
normalities, other than the fasciculations in the lower limbs
with mild asymmetrical leg weakness (Table 1, Day 1).
His mini mental state examination result of 25 andtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Cognition and neuromuscular status – amyotrophy in prion disease
Hospital day
Day 1 Day 7 Day 10 Day 16 Day 30
Cognition:
Mini mental state examination 25 - 23 9 0
Clock drawing test 4 - 3 0 0
Total functional capacity 12 - 2 1 0
Addenbrooke’s cognitive assessment (revised) 83 - 72 38 0
• Attention and orientation 16/18 - 13/18 4/18 0
• Memory 22/26 - 20/26 13/26 0
• Fluency 10/14 - 8/14 8/14 0
• Language 22/26 - 20/26 13/26 0
Visuospatial 13/16 - 11/16 0/16 0
Neuromuscular:
Neck F 5* 5 4 3 2
E 5 5 4 3 2
Hip F 4(L), 5(R) 3(L), 3(R) 3(L), 3(R) 3(L), 3(R) 2(L), 2(R)
E 4, 5 3, 3 3, 3 3, 3 2, 2
Hip ABD 4, 5 3, 4 3, 3 3, 3 2, 2
ADD 4, 5 3, 4 3, 3 3, 3 2, 2
Knee F 4, 5 3, 3 3, 3 3, 3 2, 2
E 4, 5 3, 3 3, 3 3, 3 2, 2
Ankle DF 5, 5 3, 3 3, 3 3, 3 2, 2
PF 5, 5 4, 4 3, 3 3, 3 2, 2
INV 5, 5 3, 3 2, 2 2, 2 2, 2
EV 5, 5 3, 3 2, 2 2, 2 2, 2
Shoulder ABD 5, 5 5, 5 4, 4 3, 3 2, 2
F 5, 5 5, 5 4, 4 3, 3 2, 2
E 5, 5 5, 5 4, 4 3, 3 2, 2
Elbow F 5, 5 5, 5 3, 3 3, 3 2, 2
E 5, 5 5, 5 3, 3 3, 3 2, 2
Wrist F 5, 5 5, 5 3, 3 3, 3 2, 2
E 5, 5 5, 5 3, 3 3, 3 2, 2
Finger F 5, 5 5, 5 3, 3 3, 3 2, 2
E 5, 5 5, 5 3, 3 3, 3 2, 2
*Medical Research Council Scale 0 to 5. F Flexion, E Extension, ABD Abduction, ADD Adduction, PF Plantar flexion, INV Inversion, EV Eversion, DF Dorsiflexion,
L Left, R Right.
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considered within normal limits for a French/Algerian
man of age 70 where English was not his first language.
Furthermore, his Addenbrooke’s cognitive assessment and
total functional capacity were normal. There were no
upper motor neuron signs and the patient could walk
without assistance. An initial magnetic resonance imaging
(MRI) scan did not show diagnostic abnormalities in the
brain or cervical spine. Nerve conduction studies were
normal and an electromyography (EMG) test on day 9
showed widespread active and chronic partial denervationin all skeletal muscle sampled: fibrillation and fasciculation
potentials were present in all examined muscles and in all
four limbs.
A week following presentation, our patient experienced
increased difficulty walking with worsening leg weakness
(Table 1, Day 7). The fasciculations had ascended and
were now clinically evident in the lumbar and thoracic
paraspinal muscles and upper limbs.
Electroencephalography (EEG) revealed nonspecific
slow wave changes without epileptiform activity. Our pa-
tient’s symptomatic progression continued and by day 10
Panegyres et al. Journal of Medical Case Reports 2013, 7:218 Page 3 of 6
http://www.jmedicalcasereports.com/content/7/1/218he developed worsening lower and upper limb weakness
with some decrease in his cognitive status (Table 1). On
day 16 he reported short-term memory loss and had a
supranuclear palsy of upgaze with deteriorating limb
weakness. The fasciculations had now ascended to his
neck and facial muscles. His tongue, however, remained
normal without fasciculations. There was new evidence
of a marked cognitive deterioration. Our patient’s limb
strength continued to deteriorate and he became pro-
gressively bed-bound and confused by day 30.
A second EEG on day 16 revealed increases in slow
wave activity suggestive of encephalopathy. Six days later,
the EEG demonstrated isolated epileptogenic activity in
the left temporal and parietal regions with diffuse periodic
discharges. Our patient developed catalepsy as he contin-
ued to deteriorate. The 14-3-3 protein was detected in his
cerebrospinal fluid, which was otherwise normal and with-
out malignant cells (day 20). A repeat MRI scan on day 22
revealed multiple areas of diffusion-weighted imaging
positivity in the basal ganglia, right cingulate gyrus and
the anterior border of the right caudate head suggestive of
prion disease. He did not have mutations in the prion gene
(PRPN) on gene testing and was Met/Met at codon 129.
Our patient continued to deteriorate and died 36 days
after symptom onset.
A postmortem examination revealed patchy neuronal
loss, mild reactive astrogliosis and numerous diffuse neur-
itic plaques within the brain, with several leptomeningealEsteban et al, 2001
Nowacki et al, 2000
Allen et al, 1971
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Figure 1 The course of amyotrophy in Creutzfeldt-Jakob disease.and cortical blood vessels positive for beta-amyloid: all
compatible with our patient’s age, and without neurofib-
rillary tangles. Spongiform change was widespread in the
neocortex. Immunohistological staining for the 12F10
prion antibody revealed patchy synaptic-like positivity in
the cerebral cortex, thalamus, cerebellar cortex and brain-
stem motor neurons. The brain and spinal cord were
macroscopically normal. Our mortuary does not permit
spinal cord sampling for prion disease and our neuropath-
ology laboratory does not perform prion protein isotyping.
Such observations strongly suggested an unusual form of
prion disease with prominent early involvement of anter-
ior horn cells and ascending spinal propagation.Discussion
This case report provides an insight into the presentation
and manifestations of amyotrophic features in CJD from
symptom onset to death. The presence of amyotrophy in
CJD has been previously documented [4-7], although
mostly as a terminal consequence of the disease [4]. To the
best of our knowledge, our patient is the first to have expe-
rienced amyotrophic features so early in the disease course
and to have symptoms suggestive of ascending prion
propagation from lower limbs, trunk musculature, upper
limbs and brain (Figure 1). Disease duration is typically six
months [3], making the rapidity of our patient’s deterior-
ation and death striking.40 50 60 70 80
nce of First Amyotrophic Features Disease Duration to Death
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◦ Spongiform change of temporal lobes







F 35 12 ◦ Memory loss ND 10 months
after clinical
presentation
◦ Severe spongiform change, astrocytosis in the
putamen, caudate nucleus and amygdala
◦ Diplopia ◦ Degeneration of lateral corticospinal tracts
◦ Neuronal loss of anterior horn cells
Traub et al.,
1977 [10]
M 61 9 ◦ Memory loss ND 6 months
after clinical
presentation
◦ Neurodegeneration of cerebral cortex




M 82 2 ◦ Memory loss 3 weeks 4 weeks after
symptomatic
onset
◦ Extensive spongiform change and neuronal
loss
◦ Confusion ◦ Loss of anterior horn cells
Esteban et al.,
2001 [4]




◦ Neocortical and hipppocampal spongiosis
◦ Severe neuronal loss with gliosis in the
amygdala
◦ Loss of anterior horn cells
Kovacs et al.,
2002 [7]
M 62 8 ◦ Numbness in left
foot




◦ Extensive spongiform change, neuronal loss
and astrocytosis
◦ Reduced neuronal density in ventral horn
Niewiadomska
et al., 2002 [5]
M 67 10.5 ND ND ND ND
Niewiadomska
et al., 2002 [5]
M 65 24 ND ND ND ND
Niewiadomska
et al., 2002 [5]
M 60 9 ND ND ND ND
Panegyres et
al., 2013
M 70 1.2 ◦ Limb weakness
and falls
At onset First sign at
clinical
presentation
◦ Extensive spongiform change, neuronal loss
and astrocytosis in the neocortex, with 12F10
synaptic immunopositivity in cerebral cortex,
thalamus, cerebellar cortex and brainstem motor
neurons.
ND not described.
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sporadic CJD cases [3,5]. However, quantifying the
prevalence of lower motor neuron dysfunction in CJD is
problematic in the absence of a rigorous definition [3].
Moreover, the diversity of clinical amyotrophic manifesta-
tions reported in CJD has raised doubts over the signifi-
cance of concurrent upper and lower motor neuron
involvement in prion disease.
Worrall et al. [3] report 13 patients with sporadic CJD
who demonstrate clinically relevant lower motor neuron
disease with associated electomyographic denervation
[3,4], concluding that amyotrophy is occasionally a signifi-
cant feature of CJD (readers are referred to that work for
detail of those patients). However, the clinical progression
and neuropathological findings of only three of these pa-
tients convincingly portray the emergence of amyotrophic
features with an undoubted CJD diagnosis (Table 2)
[4,7,8]. Since Worrall et al.’s findings [3], reports of amyot-
rophy in CJD have been scant, with the emergence of
lower motor neuron features vague upon a questionable
diagnosis. Nevertheless, amyotrophy has been reported in
six patients with confirmed CJD [4,5,7,8] (Table 2), al-
though only three provide detailed information of their
patient’s clinical course [4,7,8].
Amyotrophy appeared in the terminal stages of CJD for
the majority of these patients and was not an early or sole
presenting feature as in our patient (Table 2). For these
patients, prion protein propagation appeared to descend
the corticospinal tract with rapidity from the brain, to the
cervical spine and then trunk musculature; that is, in con-
trast to the ascending pattern of neurological dysfunction
witnessed in our patient. For one patient, however, amyo-
trophic features were evident at initial presentation and
remained prominent throughout the course of his disease
[9]; marked cognitive deficits including memory loss,
confabulation and constructional apraxia developed
concurrently – distinct from our patient who developed
dementia 10 days after the onset of amyotrophy.
Anterior horn cells and spinal ganglia are rarely investi-
gated, but may explain amyotrophy and peripheral denerv-
ation in some patients with sporadic CJD [5]. Significant
anterior horn cell loss was verified in five patients [4,8-10],
in conjunction with diagnostic spongiform degeneration
in the pyramidal tracts. One patient presenting with neu-
rosensory deficits demonstrated decreased motor neuron
density in the ventral horns [7]. Due to the restrictions
placed upon our mortuary techniques, our patient’s spinal
cord could not be microscopically evaluated. Nevertheless,
clinical evidence of ascending anterior horn cell involve-
ment was suggestive of upward prion propagation.
Supranuclear palsy of upgaze is sometimes found
in other neurodegenerative diseases like progressive
supranuclear palsy, but is rarely a feature of sporadic CJD
[11]. Moreover, our patient’s development of catalepsy inthe later stages of the disease is further evidence of as-
cending neurodegeneration.
The absence of upper motor neuron signs, the lack of
bulbar involvement and the rapid progression negate the
possible coexistence of amyotrophic lateral sclerosis
(ALS) and CJD. Furthermore, the findings in our patient
do not fulfill recognized diagnostic criteria for definite,
probable or possible ALS using the El Escorial, Airlie
House or Awaji-shima guidelines [12,13].
Huntington’s disease has been reported as presenting
with motor neuron disease, suggesting that anterior horn
cells are vulnerable to the effects of neurodegenerative
processes of other etiologies including trinucleotide re-
peat disorder with protein misfolding, impaired deoxy-
ribonucleic acid (DNA) transcription, ribonucleic acid
(RNA) processing interference, apoptosis, cytoplasmic
element dysfunction and glutamate excitotoxicity [14].
Conclusion
This report provides a narrative of our patient’s experience
of CJD from onset to death in just 36 days. In contrast to
previously reported cases in the literature, amyotrophic
features were the first clinical signs of the disease in the
absence of dementia. Interestingly, prion propagation
seems to have originated in the anterior horn cells,
ascended the corticospinal tracts and eventually spread to
the brain.
Consent
Written informed consent was obtained from the patient’s
next-of-kin for publication of this case report and any ac-
companying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
Competing interests
The authors have no competing interests to declare.
Authors’ contributions
EA, RS and PKP analyzed and interpreted the patient data. PKP and RS
diagnosed and managed the patient. All authors contributed to writing the
paper and approved the final manuscript.
Author details
1Neurodegenerative Disorders Research Pty Ltd, 185 York Street, Subiaco,
Perth 6008, Western Australia. 2Neurology Unit, Department of General
Medicine, Joondalup Health Campus, Shenton Avenue, Joondalup 6027,
Western Australia. 3Department of General Medicine, Joondalup Health
Campus, Shenton Avenue, Joondalup 6027, Western Australia.
Received: 26 March 2013 Accepted: 4 July 2013
Published: 23 August 2013
References
1. Brown K, Mastrianni JA: The prion diseases. J Geriatr Psychiatry Neurol 2010,
23:227–298.
2. Imran M, Mahmood S: An overview of human prion diseases. Virol J 2011,
8:559.
3. Worrall BB, Rowland LP, Chin SSM, Nastrianni JA: Amyotrophy in prion
disease. Arch Neurol 2000, 57:33–38.
Panegyres et al. Journal of Medical Case Reports 2013, 7:218 Page 6 of 6
http://www.jmedicalcasereports.com/content/7/1/2184. Esteban JCG, Atares B, Zarranz JJ, Velasco F, Lambarri I: Dementia,
amyotrophy, and periodic complexes on electroencephalogram: a
diagnostic challenge. Arch Neurol 2001, 58:1669–1672.
5. Niewiadomska M, Kulczycki J, Wochnik-Dyjas D, Szpak GM, Rakowicz MD,
Łojkowska W, Niedzielska K, Inglot E, Wieclawska M, Glazowski C,
Tarnowska-Dziduszko E: Impairment of the peripheral nervous system in
Creutzfeldt-Jakob disease. Arch Neurol 2002, 59:1430–1436.
6. Brown P: Transmissible human spongiform encephalopathy (infectious cerebral
amyloidosis): Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker
syndrome and kuru. In Neurodegenerative Diseases. Edited by Calne DB.
Philadelphia, PA: WB Saunders CO; 1994:839–876.
7. Kovacs T, Aranyi Z, Szirmai I, Lantos P: Creutzfeldt-Jakob disease with
amyotrophy and demyelinating polyneuropathy. Arch Neurol 2002,
59:1811–1814.
8. Nowacki P, Kulczycki J, Narolewska A, Grzelec: Amyotrophic form of
Creutzfeldt-Jakob disease with rapid course in 82-year-old man.
Folia Neuropathol 2000, 38:161–163.
9. Allen IV, Dermott JH, Connolly JH, Hurwitz LJ: A study of a patient with the
amyotrophic form of Creutzfelt-Jakob disease. Brain 1971, 94:715–724.
10. Traub R, Gajdusek DC, Gibb CJ: Transmissible virus dementia: the relation
of transmissible spongiform encephalopathy to Creutzfeldt-Jakob
disease. In Aging and Dementia. Edited by Smith WL, Kinsbourne M. New
York, NY: Spectrum publications; 1977:91–172.
11. Prasad S, Ko MW, Lee EB, Gonatas NK, Stern MB, Galetta S: Supranuclear
vertical gaze abnormalities in sporadic Creutzfeldt-Jakob disease.
J Neurol Sci 2007, 253:69–72.
12. Hardiman O, van den Berg LH, Kiernan MC: Clinical diagnosis and
management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011, 7:639–649.
13. Costa J, Swash M, de Carvalho M: Awaji criteria for the diagnosis of
amyotrophic lateral sclerosis. Arch Neurol 2012, 69:1410–1416.
14. Sadeghian H, O’Suilleabhain PE, Battiste J, Elliott JL, Trivedi JR: Huntington
chorea presenting with motor neuron disease. Arch Neurol 2011, 68:650–652.
doi:10.1186/1752-1947-7-218
Cite this article as: Panegyres et al.: A patient with Creutzfeldt-Jakob
disease presenting with amyotrophy: a case report. Journal of Medical
Case Reports 2013 7:218.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
